Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 118-125

John Wiley & Sons Inc

Access to resources Recommend Favorite

A different perspective on sofosbuvir‐ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital‐c network study

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 1, 2018-01 ,pp. : 56-62

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Efficacy of 24-Week Interferon Monotherapy for Type C Liver Cirrhosis in Japanese Patients with Genotype 1b and Low Virus Load

By  

Intervirology, Vol. 51, Iss. 4, 2008-10 ,pp. : 265-269

Karger

Access to resources Recommend Favorite

Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area

By  

Intervirology, Vol. 56, Iss. 3, 2013-01 ,pp. : 178-183

Karger

Access to resources Recommend Favorite

Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 79-89

John Wiley & Sons Inc

Access to resources Recommend Favorite